Lyell Immunopharma reports Q2 results
Source: SeekingAlpha
2025-08-12 17:06:18 ET
More on Lyell Immunopharma
- Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
- Lyell Immunopharma announces up to $100 million equity private placement
- Lyell Immunopharma strengthens clinical and commercial capabilities with executive appointments
- Seeking Alpha’s Quant Rating on Lyell Immunopharma
- Historical earnings data for Lyell Immunopharma
Read the full article on Seeking Alpha
For further details see:
Lyell Immunopharma reports Q2 results
Lyell Immunopharma Inc.
NASDAQ: LYEL
LYEL Trading
-2.13% G/L:
$24.37 Last:
40,301 Volume:
$24.69 Open:
LYEL Latest News
LYEL Stock Data
$503,932,654
12,184,349
0.5%
11
N/A
Biotechnology & Life Sciences
Healthcare
US
South San Francisco
